Literature DB >> 16837223

Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA gene.

Shunji Tomatsu1, Adriana M Montaño, Patricia Lopez, Georgeta Trandafirescu, Monica A Gutierrez, Hirotaka Oikawa, Tatsuo Nishioka, Matheus B Vieira, Tadao Orii, Akihiko Noguchi.   

Abstract

Design of efficient treatment strategies for diseases requires clarification of the nature of each mutation causing the disease. In this study, we have investigated three factors to correctly predict the correlation between genotype and phenotype on N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene responsible for one of lysosomal storage diseases, known as mucopolysaccharidosis IVA (MPS IVA); (i) evolutionary conservation of amino acid residues among family proteins, (ii) conservativeness of amino acid changes in GALNS, and (iii) structural conservation of amino acid residue. The results showed that (i) the likelihood of a missense variant causing MPS IVA was directly correlated with the level of evolutionary conservation and inversely correlated with conservativeness but not correlated with the structural conservation, (ii) the disease-causative mutations were 9 times more likely to be located on the 'highly conserved' residues than the polymorphisms, (iii) the likelihood of 'non-conservative' amino acid changes in missense mutations was 6.8 times higher than those in the polymorphisms, (iv) the degree of evolutionary conservation was nearly as predictive in phenotype as that of conservativeness of amino acid changes, and (v) the combination of the two factors, evolutionary conservation and conservativeness, provides a better association between missense variants and clinical severity with higher sensitivity (83.5-88.9%) and specificity (71.4-88.3%), than that obtained by either factor alone. These findings suggest that the combination of evolutionary conservation and conservativeness is a useful tool to predict the effect of each mutation on the clinical phenotype and can be applied to the analysis of phenotype/genotype relation in other genetic diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837223     DOI: 10.1016/j.ymgme.2006.05.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

Review 1.  Mucopolysaccharidosis IVA and glycosaminoglycans.

Authors:  Shaukat Khan; Carlos J Alméciga-Díaz; Kazuki Sawamoto; William G Mackenzie; Mary C Theroux; Christian Pizarro; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2016-11-29       Impact factor: 4.797

2.  Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.

Authors:  Angela C Sosa; Barbara Kariuki; Qi Gan; Alan P Knutsen; Clifford J Bellone; Miguel A Guzmán; Luis A Barrera; Shunji Tomatsu; Anil K Chauhan; Eric Armbrecht; Adriana M Montaño
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Effect of enzyme replacement therapy on the growth of patients with Morquio A.

Authors:  Caitlin Doherty; Molly Stapleton; Matthew Piechnik; Robert W Mason; William G Mackenzie; Seiji Yamaguchi; Hironori Kobayashi; Yasuyuki Suzuki; Shunji Tomatsu
Journal:  J Hum Genet       Date:  2019-04-24       Impact factor: 3.172

4.  Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  A M Montaño; K Sukegawa; Z Kato; R Carrozzo; P Di Natale; E Christensen; K O Orii; T Orii; N Kondo; S Tomatsu
Journal:  J Inherit Metab Dis       Date:  2007-09-17       Impact factor: 4.982

5.  Effect of elongation factor 1alpha promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  Carlos J Alméciga-Díaz; Maria A Rueda-Paramo; Angela J Espejo; Olga Y Echeverri; Adriana Montaño; Shunji Tomatsu; Luis A Barrera
Journal:  Mol Biol Rep       Date:  2008-11-07       Impact factor: 2.316

6.  Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels.

Authors:  Vũ Chí Dũng; Shunji Tomatsu; Adriana M Montaño; Gary Gottesman; Michael B Bober; William Mackenzie; Miho Maeda; Grant A Mitchell; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-26       Impact factor: 4.797

7.  Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A.

Authors:  Sergio Olarte-Avellaneda; Alexander Rodríguez-López; Carlos Javier Alméciga-Díaz; Luis Alejandro Barrera
Journal:  Mol Biol Rep       Date:  2014-10-07       Impact factor: 2.316

8.  Hematopoietic stem cell transplantation for Morquio A syndrome.

Authors:  Hiromasa Yabe; Akemi Tanaka; Yasutsugu Chinen; Shunichi Kato; Kazuki Sawamoto; Eriko Yasuda; Haruo Shintaku; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2015-10-01       Impact factor: 4.797

9.  Current and emerging treatments and surgical interventions for Morquio A syndrome: a review.

Authors:  Shunji Tomatsu; William G Mackenzie; Mary C Theroux; Robert W Mason; Mihir M Thacker; Thomas H Shaffer; Adriana M Montaño; Daniel Rowan; William Sly; Carlos J Alméciga-Díaz; Luis A Barrera; Yasutsugu Chinen; Eriko Yasuda; Kristen Ruhnke; Yasuyuki Suzuki; Tadao Orii
Journal:  Res Rep Endocr Disord       Date:  2012-12

10.  Neurophysiology of hearing in patients with mucopolysaccharidosis type IV.

Authors:  Kyoko Nagao; Thierry Morlet; Elizabeth Haley; Jennifer Padilla; Julianne Nemith; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-02-08       Impact factor: 4.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.